Table 3.
Rituximab biosimilars in clinical development for NHL
| Sponsor | Study design | Patient population | Comparison | Status | Clinicaltrials.gov registration |
|---|---|---|---|---|---|
| Amgen | Randomized, double-blind, Phase III | CD20-positive B-cell NHL | ABP 798 vs rituximab | Recruiting | NCT02747043 |
| Mabion SA | Randomized, double-blind, Phase III | CD20-positive DLBCL | MabionCD20 vs rituximab | Recruiting | NCT02617485 |
| Pfizer Inc. | Randomized, double-blind, Phase III | CD20-positive, low-tumor-burden FL | PF-05280586 vs rituximab | Recruiting | NCT02213263 |
| Celltrion Inc | Randomized, double-blind, Phase I/III | Advanced FL | CT-P10 + CVP vs rituximab + CVP | Active | NCT02162771 |
| Sandoz | Randomized, double-blind, Phase III | Untreated advanced FL | GP2013 vs rituximab | Active | NCT01419665 |
| Boehringer Ingelheim | Randomized, double-blind, Phase I | Low-tumor-burden FL | BI 695500 vs rituximab | Completed | NCT01950273 |
Abbreviations: CVP, cyclophosphamide, vincristine, and prednisone; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NHL, non-Hodgkin’s lymphoma.